Last reviewed · How we verify
Step-up
Step-up, developed by the University of Roma La Sapienza, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current market availability. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Step-up |
|---|---|
| Also known as | Imuran, Medrol, Urbason |
| Sponsor | University of Roma La Sapienza |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Living With Multimorbidity: Care Coordination and Symptom Management Program (COORDINATE) (NA)
- SURGIMEDIA: A Patient Randomized Control Trial of Utilization of Multimedia for Enhanced Surgical Consent (NA)
- Perioperative Telemonitoring to Optimize Cancer Care and Outcomes (NA)
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- Effects of Dual Task-Oriented Circuit Training on Walking Recovery in Sub-acute Stroke (NA)
- Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma (PHASE1, PHASE2)
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) (PHASE2)
- Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FIT (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |